About Codagenix
Codagenix is a company based in Stony Brook (United States) founded in 2011. Codagenix has raised $47.1 million across 14 funding rounds from investors including Serum Institute of India, United States Department of Agriculture and NIH. Codagenix offers products and services including Live-Attenuated Vaccines, Virotherapeutic Platform, and Codon Deoptimization Technology. Codagenix operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Adaptive Biotechnologies, among others.
- Headquarter Stony Brook, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Codagenix Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$47.1 M (USD)
in 14 rounds
-
Latest Funding Round
$10 M (USD), Grant
Oct 13, 2023
-
Investors
Serum Institute of India
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Codagenix
Codagenix offers a comprehensive portfolio of products and services, including Live-Attenuated Vaccines, Virotherapeutic Platform, and Codon Deoptimization Technology.
Vaccines engineered for infectious diseases using synthetic biology.
Therapeutics designed for cancer treatment via viral genome edits.
Technology for creating stable viral edits in animal health applications.
People of Codagenix
Unlock access to complete
Unlock access to complete
Funding Insights of Codagenix
Codagenix has successfully raised a total of $47.1M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $10 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Codagenix
Codagenix has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Serum Institute of India, United States Department of Agriculture and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is deployed for global health technology innovations.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by this single-family office.
|
Locked | Locked | Locked | |
|
Biotech sectors are targeted for investments by Topspin Fund.
|
Locked | Locked | Locked |
Investor details for Codagenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Codagenix
Investment portfolio details for Codagenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Codagenix
Detailed financials for Codagenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Codagenix Comparisons
Peer comparison for Codagenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Codagenix
Codagenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Adaptive Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
Detailed competitors of Codagenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Codagenix
Complete news archive for Codagenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Codagenix
Codagenix was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Codagenix is headquartered in Stony Brook, United States. It is registered at Stony Brook, New York, United States.
Codagenix is a funded company, having raised a total of $47.1M across 14 funding rounds to date.
Codagenix was founded in 2011 and is located in Stony Brook, United States. Live-attenuated viral vaccines are developed by the company within the biotechnology sector, focusing on infectious diseases. The proprietary SAVE platform is utilized, which employs synthetic biology to redesign the entire genome of target viruses and produce vaccine strains. Operations center on a preclinical pipeline that addresses seasonal influenza, dengue virus, respiratory syncytial virus, and pandemic influenza.
Codagenix's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Codagenix offers Live-Attenuated Vaccines, Virotherapeutic Platform, and Codon Deoptimization Technology.
Codagenix has 8 investors. Key investors include Serum Institute of India, United States Department of Agriculture, NIH, HHS, and Adjuvant Capital.